Shares of biopharmaceutical company Clovis Oncology were soaring on Wednesday after the company said the supplemental new drug application (sNDA) for its prostate cancer treatment Rubraca has been granted priority review status by the Food and Drug Administration. Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor … Continue reading “Clovis Oncology Shares Soar on Positive FDA News”
